more

Agile Therapeutics (AGRX)

(Delayed Data from OTC)

$0.40 USD

+0.03 (8.19%)

Updated Apr 24, 2024 03:03 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Bottom 36% (162 out of 252)

Industry: Medical - Generic Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on August 08,2023

Supernus (SUPN) delivered earnings and revenue surprises of -108.70% and 6.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Ardelyx (ARDX) This Year?

by Zacks Equity Research Published on February 20,2023

Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.

TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down

by Zacks Equity Research Published on February 09,2023

TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.

biotechs

Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on February 03,2023

Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.

Is Ardelyx (ARDX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on January 18,2023

Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.

BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on November 03,2022

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 8.82% and 94.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on November 02,2022

Personalis (PSNL) delivered earnings and revenue surprises of 7.94% and 5.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on March 30,2022

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of -17.65% and 3.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on March 23,2022

Homology Medicines (FIXX) delivered earnings and revenue surprises of -1.72% and 19.80%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AGRXPositive Net Change

Amphastar Pharmaceuticals (AMPH) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research Published on March 10,2022

Amphastar (AMPH) delivered earnings and revenue surprises of 10.53% and 8.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on February 24,2022

Personalis (PSNL) delivered earnings and revenue surprises of 11.76% and 0.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Agile Therapeutics (AGRX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on November 02,2021

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 5.26% and -13.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

AGRXPositive Net Change

Agile Therapeutics (AGRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on July 26,2021

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 4.76% and -18.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

AGRXPositive Net Change

Agile Therapeutics (AGRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on May 04,2021

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 9.09% and -82.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

AGRXPositive Net Change

Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on March 01,2021

Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 13.04% and -25.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?